Najat Khan Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

RXRX Quotes by TradingView

Najat Khan is Chief R&D Commercial Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 708,585 shares of RXRX, which is worth approximately $3.56 Million. The most recent transaction as insider was on May 15, 2025, when has been sold 3,796 shares (Class A Common Stock) at a price of $4.25 per share, resulting in proceeds of $16,133. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 709K
0.53% 3M change
n/a 12M change
Total Value Held $3.56 Million

Najat Khan Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 15 2025
SELL
Payment of exercise price or tax liability
$16,133 $4.25 p/Share
3,796 Reduced 0.53%
708,585 Class A Common Stock
Feb 03 2025
SELL
Payment of exercise price or tax liability
$19,959 $7.25 p/Share
2,753 Reduced 0.38%
712,381 Class A Common Stock
Feb 03 2025
BUY
Grant, award, or other acquisition
-
218,162 Added 23.38%
715,134 Class A Common Stock
Aug 01 2024
BUY
Grant, award, or other acquisition
-
496,972 Added 50.0%
496,972 Class A Common Stock
NK

Najat Khan

Chief R&D Commercial Officer
Salt Lake City, UT

Track Institutional and Insider Activities on RXRX

Follow RECURSION PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on RXRX